Epothilone D (Kosan/Roche)

Current Opinion in Investigational Drugs

Volumn 5, Issue 6, 2004, Pages 657-667

  Kolman, Ada ^a  

^a STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DESOXYEPOTHILONE B; EPOTHILONE DERIVATIVE; NEW DRUG;

ANIMAL; CHEMISTRY; DRUG SCREENING; HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; EPOTHILONES; HUMANS;

EID: 4043177145     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. 150199 The first of the taxanes, an important new class of antitumor agents. Rowinsky EK, Onetto N, Canetta RM, Arbuck SG SEMIN ONCOL 1992 19 6 646-662
2. 243573 Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol). Kowalski RJ, Giannakakou P, Hamel E J BIOL CHEM 1997 272 4 2534-2541
3. 243588 Epothilones A and B: Antifungal and cytotoxic compounds from Sorangium cellulosum (myxobacteria). Production, physico-chemical and biological properties. Gerth K, Bedorf N, Hofle G, Irschik H, Reichenbach H J ANTIBIOT (TOKYO) 1996 49 6 560-563
4. 243591 Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, Goetz M, Lazarides E, Woods CM CANCER RES 1995 55 11 2325-2333
5. 297265 Desoxyepothilone B: An efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. Chou TC, Zhang XG, Balog A, Su DS, Meng D, Savin K, Bertino JR, Danishefsky SJ PROC NATL ACAD SCI USA 1998 95 16 9642-9647
6. 314823 Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. Chou TC, Zhang XG, Harris CR, Kuduk SD, Balog A, Savin KA, Bertino JR, Danishefsky SJ PROC NATL ACAD SCI USA 1998 95 26 15798-15802
7. 397426 Kosan receives NCI grant for production of the anticancer agent epothilone. Kosan Biosciences Inc PRESS RELEASE 2001 January 30
8. 405234 Kosan announces issuance of US patent for epothilone D chemical synthesis technology. Kosan Biosciences Inc PRESS RELEASE 2001 April 10
9. 407449 New class of microtubule targeting antitumor agents: Desoxyepothilone B and desoxyepothilone F. Chou TC, Guan YB, Zhang XG, Lee C, Stachel SJ, Bertino JR, Danichefsky SJ PROC ANNU MEET AM ASSOC CANCER RES 2001 42 Abs 1997
10. 420432 Cloning and heterologous expression of the epothilone gene cluster. Tang L, Shah S, Chung L, Carney J, Katz L, Khosla C, Julien B SCIENCE 2000 287 5453 640-642
11. 427279 Kosan initiates phase I clinical trial of epothilone D for advanced cancer. Kosan Biosciences Inc PRESS RELEASE 2001 October 29
12. 427541 Kosan announces issuance of US patent for production of epothilone D. Kosan Biosciences Inc PRESS RELEASE 2001 October 31
13. 446524 Metabolism and pharmacokinetics of KOS-862 (epothilone D) in the rat and dog. Hoch U, Carney JR, Johnson Jr RG, Hannah A PROC ANNU MEET AM ASSOC CANCER RES 2002 43 Abs 2118
14. 446959 Antitumor activity of KOS-862 (epothilone D) produced via a genetically engineered host. Johnson RG Jr, Qiu RG, Chou TC PROC ANNU MEET AM ASSOC CANCER RES 2002 43 Abs 3925
15. 447113 Subcellular distribution of epothilones in human tumor cells. Lichtner RB, Rotgeri A, Bunte T, Buchman B, Hoffmann J, Schwede W, Skuballa W, Klar U PROC NATL ACAD SCI USA 2001 98 20 11743-11748
16. 447612 Repeat dose toxicity study of EpoD (12,13-desoxyepothilone B, NSC-703147) in beagle dogs. Frantz CE, Fairchild D, Melton S, Helm J, Brune J, Phillips S, Schweikart K, Tomaszewski JE, Mirsalis JC PROC ANNU MEET AM ASSOC CANCER RES 2002 43 Abs 5413
17. 452025 KOS-862 (epothilone D): Results of a phase I dose-escalating trial in patients with advanced malignancies. Rosen PJ, Rosen LS, Britten C, Parson M, Cropp GF, McDaid H, Han J, Johnson RG, Hannah AL PROC AM SOC CLIN ONCOL 2002 21 Abs 413
18. 457405 Kosan announces issuance of key US patent for recombinant Epothilone D - KOS-862 - producing microorganism. Kosan Biosciences Inc PRESS RELEASE 2002 July 09
19. 462641 New natural epothilones from Sorangium cellulosum. Strains So ce90/B2 and So ce90/D13: Isolation, structure elucidation, and SAR studies. Hardt IH, Steinmetz H, Gerth K, Sasse F, Reichenbach H, Hofle G J NAT PROD 2001 64 7 847-856
20. 462647 Isolation and characterization of the epothilone biosynthetic gene cluster from Sorangium cellulosum. Julien B, Shah S, Ziermann R, Goldman R, Katz L, Khosla C GENE 2000 249 1-2 153-160
21. 462703 Total syntheses of epothilones B and D. Multzer J, Mantoulidis A, Ohler E J ORG CHEM 2000 65 22 7456-7467
22. 462707 Total synthesis of epothilone B, epothilone D and cis- and trans-9,10-dehydroepothilone D. White JD, Carter RG, Sundermann KF, Wartmann M J AM CHEM SOC 2001 123 23 5407-5413
23. 462708 Catalytic antibody route to the naturally occurring epothilones: Total synthesis of epothilones A-F. Sinha SC, Sun J, Miller GP, Wartmann M, Lerner RA CHEM EUR J 2001 7 8 1691-1702
24. 463228 Heterologous expression of epothilone biosynthetic genes in Myxococcus xanthus. Julien B, Shah S ANTIMICROB AGENTS CHEMOTHER 2002 46 9 2772-2778
25. 464941 Roche and Kosan to jointly develop and commercialize Kosan's epothilone D as an anticancer agent. Roche/Kosan Biosciences Incorporated PRESS RELEASE 2002 September 23
26. 470694 Phase I dose-escalating trial of KOS-862 (epothilone D) in patients with advanced malignancies. Rosen L, Kabbinavar F, Rosen P, Hecht JR, Parson M, Cropp G, McDaid H, Han J, Johnson R, Hannah A AACR NCI EORTC MOL TARGETS CANCER THER 2002 19-22 November Abs 123
27. 474959 Recent developments in the chemistry, biology and medicine of the epothilones. Nicolaou KC, Ritzen A, Namoto K CHEM COMM 2001 7 17 1523-1535
28. 485324 KOS-862 (epothilone D) with 5-fluorouracil in human colon cancer cell lines: Synergistic antitumor effects. Zhou Y, Liu F, Feng L, Uphoff J, Ma W, Hannah AL, Johnson RG Jr PROC ANNU MEET AM ASSOC CANCER RES 2003 44 Abs 2746
29. 486968 Synthesis and biological evaluation of highly potent analogues of epothilones B and D. Altmann KH, Bold G, Caravatti G, Florsheimer A, Guagnano V, Wartmann M BIOORG MED CHEM LETT 2000 10 24 2765-2768
30. 487131 Kosan reports first quarter financial results. Kosan Biosciences Inc PRESS RELEASE 2003 April 24
31. 487958 Epothilones and related structures - a new class of microtubule inhibitors with potent in vivo antitumor activity. Altmann KH, Wartmann M, O'Reilly T BIOCHIM BIOPHYS ACTA 2000 1470 3 M79-M91
32. 488104 Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Blagosklonny MV, Schutle T, Nguyen P, Trepel J, Neckers LM CANCER RES 1996 56 8 1851-1854
33. 488105 The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Rowinsky EK ANNU REV MED 1997 48 353-374
34. 490137 Total synthesis of epothilones B and D: Applications of allylstannanes in organic synthesis. Martin N, Thomas EJ TETRAHEDRON LETT 2001 42 47 8373-8377
35. 491168 KOS-862 (epothilone D): A comparison of two schedules in patients with advanced malignancies. Piro LD, Rosen LS, Parson M, Cropp GP, McDaid H, Han J, Matela J, Johnson RG, Hannah AL PROC AM SOC CLIN ONCOL 2003 22 Abs 539
36. 491863 Kosan and Roche present favorable phase I results of KOS-862 (epothilone D), at the American Society of Clinical Oncology annual meeting. Kosan Biosciences Inc, Hoffmann-La Roche Inc PRESS RELEASE 2003 June 02
37. 493144 KOS-862 (epothilone D): Phase I dose escalating and pharmacokinetic (PK) study in patients with advanced malignancies. Spriggs DR, Dupont J, Pezzulli S, Larkin J, Johnson RG, Hannah AL, Cropp HG, McDaid H PROC AM SOC CLIN ONCOL 2003 22 Abs 894
38. 496917 Oral bioavailability of KOS-862 (epothilone D), a potent stabilizer of microtubulin polymerization in rats and beagle dogs. Johnson RG, Carney J, Zhong Z, Cropp G, Sherrill M PROC ANNU MEET AM ASSOC CANCER RES 2003 44 Abs 5339
39. 498897 Kosan reports second quarter and six month financial results. Kosan Biosciences Inc PRESS RELEASE 2003 July 24
40. 505330 Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics. Goncalves A, Braguer D, Kamath K, Martello L, Briand C, Horwitz S, Wilson L, Jordan MA PROC NATL ACAD SCI USA 2001 98 20 11737-11742
41. 505999 Kosan presents results of second phase I trial of KOS-862 (epothilone D); data demonstrate tolerability and preliminary evidence of anti-tumor activity. Kosan Biosciences Inc PRESS RELEASE 2003 September 23
42. 516500 Phase II clinical trials of KOS-862 (epothilone D) initiated. Kosan Biosciences Inc PRESS RELEASE 2003 December 08
43. 517760 Crystal structures of epothilone D-bound, epothilone B-bound, and substrate-free forms of cytochrome P450epoK. Nagano S, Li H, Shimizu H, Nishida C, Ogura H, Ortiz de Montellano PR, Poulos TL J BIOL CHEM 2003 278 45 44886-44893
44. 517761 Generation of novel epothilone analogs with cytotoxic activity by biotransformation. Tang L, Qiu RG, Li Y, Katz L J ANTIBIOT (TOKYO) 2003 56 1 16-23
45. 517763 A new cytotoxic epothilone from modified polyketide synthases heterologously expressed in Myxococcus xanthus. Arslanian RL, Tang LI, Blough S, Ma W, Qiu RG, Katz L, Carney JR J NAT PROD 2002 65 7 1061-1064
46. 517765 Modulation of epothilone analog production through media design. Frykman S, Tsuruta H, Lau J, Regentin R, Ou S, Reeves C, Carney J, Santi D, Licari P J INDUSTRIAL MICROBIOLOGY BIOTECH 2002 28 1 17-20
47. 517766 Optimizing the heterologous production of epothilone D in Myxococcus xanthus. Lau J, Frykman S, Regentin R, Ou S, Tsuruta H, Licari P BIOTECHNOL BIOENG 2002 78 3 280-288
48. 517914 Synthesis of epothilones B and D from D-glucose. Ermolenko MS, Potier P TETRAHEDRON LETT 2002 43 16 2895-2898
49. 517915 Pre-clinical in vitro and in vivo studies of epothilone D. A novel tubulin stabilizing anti-cancer agent. Wang H, Wang S, Wang Z, Li M, Nan L, Tomaszewski JE, Rhie JK, Zhang R, Hill DL CLIN CANCER RES 2001 7 3810S
50. 517916 In vitro metabolism of 12,13-desoxyepothilone B (EPOD) in plasma and liver microsomes from different species. Hoch U, Carney JR, Ashley GW, Qiu RG, Dillon SB DRUG METAB REV 2001 33 94
51. 517918 The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: Curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice. Chou TC, O'Connor OA, Tong WP, Guan Y, Zhang ZG, Stachel SJ, Lee C, Danishefsky SJ PROC NATL ACAD SCI USA 2001 98 14 8113-8118
52. 517938 Studies on the biosynthesis of epothilones: The PKS and epothilone C/D monooxygenase. Gerth K, Steinmetz H, Hofle G, Reichenback H J ANTIBIOT (TOKYO) 2001 54 2 144-148
53. 523307 Nanomolar concentrations of epothilone D inhibit the proliferation of glioma cells and severely affect their tubulin skeleton. Dietzmann A, Kanakis D, Kirches E, Kropf S, Mawrin C, Dietzmann K J NEURO ONCOL 2003 65 2 99-106
54. 526235 Kosan initiates first KOS-862 phase Ib chemotherapy combination trial. Kosan Biosciences Inc PRESS RELEASE 2004 March 04
55. 531790 Kosan Biosciences. Flanigan ADAMS HARKNESS & HILL 2004 March 04